Recent corporate updates from Eledon Pharmaceuticals highlight a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the pathway to initiate a global Phase 3 clinical trial of tegoprubart in kidney transplantation. Additionally, the company presented encouraging long-term Phase 2 data demonstrating sustained kidney function compared to standard therapies, alongside updated islet cell transplantation results showing continued insulin independence in patients with type 1 diabetes.